Identify competitor trials including patient segments of interest

This guide will help you benchmark competitor clinical trials focused on a specific patient population to evaluate their endpoints, biomarkers and outcomes to potentially redesign your next studies and increase the chances of success.

Cortellis editors gather insights from clinical trial registries, conferences, press releases and other sources to help you access that information all in one place. They also index clinical trials by condition, target, sponsor, patient segments and many other fields -available in filters- allowing you to quickly understand competitor trials details.

Cortellis Clinical Trials Intelligence provides you with patient segments including gene mutations in comparative tables and charts for easy visualization.

Example: Find clinical trials studying breast cancer in patients with AKT mutations. Are results available? Which endpoints have been included? Have these endpoints been met?

1. Quick search 'Breast tumor' and select 'Clinical Trials' on the left menu under Report Type.



© 2024 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

2. Apply filters to narrow down results by:
    a. Condition: breast tumor. Please use hierarchical filters to automatically include subcategories.



    b. Patient segment: AKT



© 2024 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

3. A comparative results table allows you to evaluate biomarkers, primary endpoint completion dates, recruitment status and more (please scroll to the right to see more). Click on the title of a trial of interest to read more details.

Title	Patient Segment	All Endpoints	Primary Endpoint Completion Date	Trial Arms Descriptions	Biomarkers
	Filters : [22] Clear	Filters : [0]	Filters : [0]		Filters : [0]
Safety, Tolerability and Potential Anti-cancer Activity of Increasing Doses of AZD-5363 in Different Treatment Schedules	Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer; Breast tumor - Subjects with Treatment Resistant Disease; Breast tumor - Subjects with gene variants - AKT1_HUMAN_Mutation;	Breast tumor - Assessment of Laboratory/Diagnostic Measures; Breast tumor - Assessment of Mortality/Death Rates; Breast tumor - Assessment of Organ Function; Breast tumor - Assessment of	26-Apr-2019 (Actual)	Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment to cessation of therapy combined with background therapy of fulvestrant at its licensed dose of 500mg intramuscularly on days 1,15,29 and once	Cell-free DNA ; Estrogen receptor ; GSK3-beta interaction protein ; Glucose ; HER2 ; Hemoglobin A, glycosylated ; Insulin ; Left ventricular ejection fraction ; Phosphatidylinositol 3-Kinase ; Phosphatidylinositol-3,4,5-
Phase I, Dose-Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients	Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer; Breast tumor - Subjects with Unresectable Tumor; Breast tumor - Subjects with gene variants - AKT1_HUMAN_rs121434592(A)	Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters; Breast tumor - Assessment of Response Rates (RR); Breast tumor - Assessment of adverse events; Solid tumor - Assessment of	31-Jul-2016 (Actual)		Alanine transaminase ; Alkaline phosphatase ; Aspartate aminotransferase ; Gamma-glutamyltranspeptidase 1 ; RAC-alpha serine/threonine-protein kinase

4. The Protocols & Results tab provides details of trial arms, results and adverse events (if any).



Scroll down to read results and identify adverse events found in this trial.



© 2024 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

5. The Subjects & Measurements tab provides eligibility criteria, biomarkers and patient segmentation as well as primary and secondary endpoints included in this trial.



Scroll down to identify biomarkers included. Further information on biomarkers can be found in Cortellis Drug Discovery Intelligence, depending on your company's subscription.



6. Back in the results page, you can change views at the top right to display a bar chart and visualize the top 10 endpoints included in these trials. Click on any of the bars to display the relevant trials as a table.



To find out what's included in your subscription, contact your Clarivate account manager or **LS Product Support.**

© 2024 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.